In-depth evaluation of commercially available human vascular smooth muscle cells phenotype: Implications for vascular tissue engineering

Sara B.H. Timraz, Ilyas A.H. Farhat, Ghada Alhussein, Nicolas Christoforou, Jeremy Teo

Research output: Contribution to journalArticle

Abstract

In vitro research on vascular tissue engineering has extensively used isolated primary human or animal smooth muscle cells (SMC). Research programs that lack such facilities tend towards commercially available primary cells sources. Here, we aim to evaluate the capacity of commercially available human SMC to maintain their contractile phenotype, and determine if dedifferentiation towards the synthetic phenotype occurs in response to conventional cell culture and passaging without any external biochemical or mechanical stimuli. Lower passage SMC adopted a contractile phenotype marked by a relatively slower proliferation rate, higher expression of proteins of the contractile apparatus and smoothelin, elongated morphology, and reduced deposition of collagen types I and III. As the passage number increased, migratory capacity was enhanced, average cell speed, total distance and net distance travelled increased up to passage 8. Through the various assays, corroborative evidence pinpoints SMC at passage 7 as the transition point between the contractile and synthetic phenotypes, while passage 8 distinctly and consistently exhibited characteristics of synthetic phenotype. This knowledge is particularly useful in selecting SMC of appropriate passage number for the target vascular tissue engineering application, for example, a homeostatic vascular graft for blood vessel replacement versus recreating atherosclerotic blood vessel model in vitro.

Original languageEnglish (US)
Pages (from-to)168-176
Number of pages9
JournalExperimental Cell Research
Volume343
Issue number2
DOIs
StatePublished - May 1 2016

Fingerprint

Tissue Engineering
Vascular Smooth Muscle
Smooth Muscle Myocytes
Blood Vessels
Phenotype
Contractile Proteins
Collagen Type III
Collagen Type I
Research
Cell Culture Techniques
Transplants
In Vitro Techniques

Keywords

  • Phenotype
  • Phenotypic modulation
  • Smooth muscle cell
  • Tissue engineering

ASJC Scopus subject areas

  • Cell Biology

Cite this

In-depth evaluation of commercially available human vascular smooth muscle cells phenotype : Implications for vascular tissue engineering. / Timraz, Sara B.H.; Farhat, Ilyas A.H.; Alhussein, Ghada; Christoforou, Nicolas; Teo, Jeremy.

In: Experimental Cell Research, Vol. 343, No. 2, 01.05.2016, p. 168-176.

Research output: Contribution to journalArticle

Timraz, Sara B.H. ; Farhat, Ilyas A.H. ; Alhussein, Ghada ; Christoforou, Nicolas ; Teo, Jeremy. / In-depth evaluation of commercially available human vascular smooth muscle cells phenotype : Implications for vascular tissue engineering. In: Experimental Cell Research. 2016 ; Vol. 343, No. 2. pp. 168-176.
@article{83f3365726944a36bb833e9f84874e07,
title = "In-depth evaluation of commercially available human vascular smooth muscle cells phenotype: Implications for vascular tissue engineering",
abstract = "In vitro research on vascular tissue engineering has extensively used isolated primary human or animal smooth muscle cells (SMC). Research programs that lack such facilities tend towards commercially available primary cells sources. Here, we aim to evaluate the capacity of commercially available human SMC to maintain their contractile phenotype, and determine if dedifferentiation towards the synthetic phenotype occurs in response to conventional cell culture and passaging without any external biochemical or mechanical stimuli. Lower passage SMC adopted a contractile phenotype marked by a relatively slower proliferation rate, higher expression of proteins of the contractile apparatus and smoothelin, elongated morphology, and reduced deposition of collagen types I and III. As the passage number increased, migratory capacity was enhanced, average cell speed, total distance and net distance travelled increased up to passage 8. Through the various assays, corroborative evidence pinpoints SMC at passage 7 as the transition point between the contractile and synthetic phenotypes, while passage 8 distinctly and consistently exhibited characteristics of synthetic phenotype. This knowledge is particularly useful in selecting SMC of appropriate passage number for the target vascular tissue engineering application, for example, a homeostatic vascular graft for blood vessel replacement versus recreating atherosclerotic blood vessel model in vitro.",
keywords = "Phenotype, Phenotypic modulation, Smooth muscle cell, Tissue engineering",
author = "Timraz, {Sara B.H.} and Farhat, {Ilyas A.H.} and Ghada Alhussein and Nicolas Christoforou and Jeremy Teo",
year = "2016",
month = "5",
day = "1",
doi = "10.1016/j.yexcr.2016.04.004",
language = "English (US)",
volume = "343",
pages = "168--176",
journal = "Experimental Cell Research",
issn = "0014-4827",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - In-depth evaluation of commercially available human vascular smooth muscle cells phenotype

T2 - Implications for vascular tissue engineering

AU - Timraz, Sara B.H.

AU - Farhat, Ilyas A.H.

AU - Alhussein, Ghada

AU - Christoforou, Nicolas

AU - Teo, Jeremy

PY - 2016/5/1

Y1 - 2016/5/1

N2 - In vitro research on vascular tissue engineering has extensively used isolated primary human or animal smooth muscle cells (SMC). Research programs that lack such facilities tend towards commercially available primary cells sources. Here, we aim to evaluate the capacity of commercially available human SMC to maintain their contractile phenotype, and determine if dedifferentiation towards the synthetic phenotype occurs in response to conventional cell culture and passaging without any external biochemical or mechanical stimuli. Lower passage SMC adopted a contractile phenotype marked by a relatively slower proliferation rate, higher expression of proteins of the contractile apparatus and smoothelin, elongated morphology, and reduced deposition of collagen types I and III. As the passage number increased, migratory capacity was enhanced, average cell speed, total distance and net distance travelled increased up to passage 8. Through the various assays, corroborative evidence pinpoints SMC at passage 7 as the transition point between the contractile and synthetic phenotypes, while passage 8 distinctly and consistently exhibited characteristics of synthetic phenotype. This knowledge is particularly useful in selecting SMC of appropriate passage number for the target vascular tissue engineering application, for example, a homeostatic vascular graft for blood vessel replacement versus recreating atherosclerotic blood vessel model in vitro.

AB - In vitro research on vascular tissue engineering has extensively used isolated primary human or animal smooth muscle cells (SMC). Research programs that lack such facilities tend towards commercially available primary cells sources. Here, we aim to evaluate the capacity of commercially available human SMC to maintain their contractile phenotype, and determine if dedifferentiation towards the synthetic phenotype occurs in response to conventional cell culture and passaging without any external biochemical or mechanical stimuli. Lower passage SMC adopted a contractile phenotype marked by a relatively slower proliferation rate, higher expression of proteins of the contractile apparatus and smoothelin, elongated morphology, and reduced deposition of collagen types I and III. As the passage number increased, migratory capacity was enhanced, average cell speed, total distance and net distance travelled increased up to passage 8. Through the various assays, corroborative evidence pinpoints SMC at passage 7 as the transition point between the contractile and synthetic phenotypes, while passage 8 distinctly and consistently exhibited characteristics of synthetic phenotype. This knowledge is particularly useful in selecting SMC of appropriate passage number for the target vascular tissue engineering application, for example, a homeostatic vascular graft for blood vessel replacement versus recreating atherosclerotic blood vessel model in vitro.

KW - Phenotype

KW - Phenotypic modulation

KW - Smooth muscle cell

KW - Tissue engineering

UR - http://www.scopus.com/inward/record.url?scp=84964267409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964267409&partnerID=8YFLogxK

U2 - 10.1016/j.yexcr.2016.04.004

DO - 10.1016/j.yexcr.2016.04.004

M3 - Article

C2 - 27079869

AN - SCOPUS:84964267409

VL - 343

SP - 168

EP - 176

JO - Experimental Cell Research

JF - Experimental Cell Research

SN - 0014-4827

IS - 2

ER -